Reductive Adjuvant Nanosystem for Alleviated Atopic Dermatitis Syndromes

IF 15.8 1区材料科学 Q1 CHEMISTRY, MULTIDISCIPLINARY

ACS Nano Pub Date : 2025-01-23 DOI:10.1021/acsnano.4c08767

Yichao Lu, Xinyu Shan, Jiaxin Huang, Huanli Zhou, Ying Zhu, Sijie Wang, Zhenyu Luo, Xu Liu, Xuemeng Guo, Yingying Shi, Yilong Hu, Huihui Liu, Junlei Zhang, Ping Huang, Lihua Luo, Jian You

{"title":"Reductive Adjuvant Nanosystem for Alleviated Atopic Dermatitis Syndromes","authors":"Yichao Lu, Xinyu Shan, Jiaxin Huang, Huanli Zhou, Ying Zhu, Sijie Wang, Zhenyu Luo, Xu Liu, Xuemeng Guo, Yingying Shi, Yilong Hu, Huihui Liu, Junlei Zhang, Ping Huang, Lihua Luo, Jian You","doi":"10.1021/acsnano.4c08767","DOIUrl":null,"url":null,"abstract":"Atopic dermatitis (AD) is a recurrent and chronic inflammatory skin condition characterized by a high lifetime prevalence and significant impairment of patients’ quality of life, primarily due to intense itching and discomfort. However, current pharmacological interventions provide only moderate efficacy and are frequently accompanied by adverse side effects. The immune-pathogenesis of AD involves dysregulation of the Th2 immune response and exacerbation of inflammation related to excessive reactive oxygen species (ROS). Therefore, to address these issues, in this study, we targeted the upstream pathogenesis by designing a pro-Th1 adjuvant nanoemulsion loaded with poly(I:C) and encapsulated with the ROS-scavenger vitamin E, termed PV-NE. PV-NE effectively rebalanced the Th1/Th2 immune response and reduced ROS levels both <i>in vivo</i> and <i>ex vivo</i>, leading to the restoration of immune balance in AD-affected skin and alleviation of symptoms such as lichenification and erythematous patches. In conclusion, our development of the reductive adjuvant nanosystem PV-NE demonstrates its biocompatibility and efficacy in combating AD progression without the use of immunosuppressant glucocorticoids. This has the potential to significantly impact the design and enhancement of pharmacotherapy in future clinical research aimed at curing AD.","PeriodicalId":21,"journal":{"name":"ACS Nano","volume":"206 1","pages":""},"PeriodicalIF":15.8000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Nano","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1021/acsnano.4c08767","RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Atopic dermatitis (AD) is a recurrent and chronic inflammatory skin condition characterized by a high lifetime prevalence and significant impairment of patients’ quality of life, primarily due to intense itching and discomfort. However, current pharmacological interventions provide only moderate efficacy and are frequently accompanied by adverse side effects. The immune-pathogenesis of AD involves dysregulation of the Th2 immune response and exacerbation of inflammation related to excessive reactive oxygen species (ROS). Therefore, to address these issues, in this study, we targeted the upstream pathogenesis by designing a pro-Th1 adjuvant nanoemulsion loaded with poly(I:C) and encapsulated with the ROS-scavenger vitamin E, termed PV-NE. PV-NE effectively rebalanced the Th1/Th2 immune response and reduced ROS levels both in vivo and ex vivo, leading to the restoration of immune balance in AD-affected skin and alleviation of symptoms such as lichenification and erythematous patches. In conclusion, our development of the reductive adjuvant nanosystem PV-NE demonstrates its biocompatibility and efficacy in combating AD progression without the use of immunosuppressant glucocorticoids. This has the potential to significantly impact the design and enhancement of pharmacotherapy in future clinical research aimed at curing AD.

Abstract Image

查看原文本刊更多论文

减轻特应性皮炎综合征的还原佐剂纳米系统

特应性皮炎（AD）是一种复发性和慢性炎症性皮肤病，其特点是终生患病率高，患者的生活质量显著受损，主要是由于强烈的瘙痒和不适。然而，目前的药物干预仅提供中等疗效，并经常伴有不良副作用。AD的免疫发病机制涉及Th2免疫反应失调和与活性氧（ROS）过多相关的炎症加剧。因此，为了解决这些问题，在本研究中，我们设计了一种负载聚（I:C）并包被ros清除剂维生素E （PV-NE）的亲th1佐剂纳米乳，以上游致病机制为目标。PV-NE在体内和体外都能有效地重新平衡Th1/Th2免疫反应，降低ROS水平，从而恢复ad感染皮肤的免疫平衡，减轻地衣变和红斑斑块等症状。总之，我们开发的还原性佐剂纳米系统PV-NE证明了其生物相容性和在不使用免疫抑制剂糖皮质激素的情况下对抗AD进展的有效性。这有可能对未来治疗阿尔茨海默病的临床研究中药物治疗的设计和增强产生重大影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Nano 工程技术-材料科学：综合

CiteScore

26.00

自引率

4.10%

发文量

1627

审稿时长

1.7 months

期刊介绍： ACS Nano, published monthly, serves as an international forum for comprehensive articles on nanoscience and nanotechnology research at the intersections of chemistry, biology, materials science, physics, and engineering. The journal fosters communication among scientists in these communities, facilitating collaboration, new research opportunities, and advancements through discoveries. ACS Nano covers synthesis, assembly, characterization, theory, and simulation of nanostructures, nanobiotechnology, nanofabrication, methods and tools for nanoscience and nanotechnology, and self- and directed-assembly. Alongside original research articles, it offers thorough reviews, perspectives on cutting-edge research, and discussions envisioning the future of nanoscience and nanotechnology.